4.6 Review

Repetitive Transcranial Magnetic Stimulation as a Therapeutic and Probe in Schizophrenia: Examining the Role of Neuroimaging and Future Directions

Journal

NEUROTHERAPEUTICS
Volume 18, Issue 2, Pages 827-844

Publisher

SPRINGER
DOI: 10.1007/s13311-021-01046-1

Keywords

Repetitive transcranial magnetic stimulation; Schizophrenia; fMRI; MRI

Funding

  1. National Institute of Mental Health [R21MH119564]
  2. NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation

Ask authors/readers for more resources

Schizophrenia is a complex condition with numerous negative outcomes, and existing treatments may not be effective for all individuals. Repetitive transcranial magnetic stimulation (rTMS) has shown potential as a novel therapeutic intervention for schizophrenia, despite mixed results in studies. Advances in rTMS technology, including the integration with neuroimaging, offer hope for improved understanding and treatment of schizophrenia.
Schizophrenia is a complex condition associated with perceptual disturbances, decreased motivation and affect, and disrupted cognition. Individuals living with schizophrenia may experience myriad poor outcomes, including impairment in independent living and function as well as decreased life expectancy. Though existing treatments may offer benefit, many individuals still experience treatment resistant and disabling symptoms. In light of the negative outcomes associated with schizophrenia and the limitations in currently available treatments, there is a significant need for novel therapeutic interventions. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that can modulate the activity of discrete cortical regions, allowing direct manipulation of local brain activation and indirect manipulation of the target's associated neural networks. rTMS has been studied in schizophrenia for the treatment of auditory hallucinations, negative symptoms, and cognitive deficits, with mixed results. The field's inability to arrive at a consensus on the use rTMS in schizophrenia has stemmed from a variety of issues, perhaps most notably the significant heterogeneity amongst existing trials. In addition, it is likely that factors specific to schizophrenia, rather than the rTMS itself, have presented barriers to the interpretation of existing results. However, advances in approaches to rTMS as a biologic probe and therapeutic, many of which include the integration of neuroimaging with rTMS, offer hope that this technology may still play a role in improving the understanding and treatment of schizophrenia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available